Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00876993
Other study ID # ACH-CNS-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2008
Est. completion date September 2015

Study information

Verified date June 2023
Source Johns Hopkins All Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.


Description:

Bevacizumab dosing is 10 mg/kg on day 1 and day 15 of a 28 days course given IV. Irinotecan dosing is 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the MTD of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150 mg/m2. For dose level 0 Temozolomide, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO. Doses will be escalated according to standard phase I dose escalation criteria.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender All
Age group 18 Months to 23 Years
Eligibility Inclusion Criteria: - Medulloblastomas, high-grade glioma, low-grade glioma, and ependymoma are eligible. Other central nervous system tumors may be considered for treatment at discretion of investigator. Pathology is required unless diffuse intrinsic pontine glioma or optic pathway tumor. - The patient should have failed first line therapy and be considered refractory, relapsed, or recurrent. Exceptions are high grade gliomas including brain stem gliomas. - Age 18 months though age 23 years are eligible for this protocol. - The patient may have received any of the agents, but not in this combination. Patients will not be eligible if they have received the combination of bevacizumab and IV irinotecan as prior therapy. They will not be eligible if they had progressive disease on any of these agents. Investigator discretion may also be used. - Bone marrow should be recovered from prior therapy with ANC >1500 and platelets >100,000. - Serum creatinine should be less than institutional upper limit of norm. - ALT/AST <3 times normal and bilirubin <1.5 times normal. - Neurologic symptoms should be stable for 1 week with stable or decreasing doses of steroids. - Patients should not be pregnant or breast feeding. Exclusion Criteria: - Patients with bleeding disorders or on anticoagulants. - Uncontrolled hypertension. - Other risks of bleeding determined on individual basis. - Patients receiving enzyme inducing anticonvulsants. - Patients with significant cardiac or pulmonary dysfunction that would compromise the patient's ability to tolerate protocol therapy or would likely interfere with the study procedures or results. - For patients receiving bevacizumab, those who have had surgical procedures should not receive bevacizumab within 28 days of a major procedure, 14 days of an intermediate procedure and 7 days of a minor procedure. Lumbar punctures or placement of PICC lines are not considered minor procedures and may occur at any time prior to or during therapy.

Study Design


Intervention

Drug:
Bevacizumab
Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
Irinotecan
Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
Temozolomide
For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)

Locations

Country Name City State
United States Johns Hopkins All Children's Hospital Saint Petersburg Florida

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins All Children's Hospital Brain Tumor Alliance, The V Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of Number of Adverse Events Collect and grade the all of the adverse events to evaluate for safety. This data was collected for the first 2 cycles for each participant. Two 28-day cycles
Secondary Best Response of Children With Recurrent or Refractory Central Nervous System Tumors With This Combination of Chemotherapy Agents. Best response by MRIs per definitions in the protocol (complete response, partial response, stable disease, progressive disease). MRI's were obtained every 2 cycles and the best response was reported. Every 2 cycles up to 24 cycles
Secondary 2 Year Event Free Survival With Children Treated With This Regimen. 2 year actual event free survival.with children treated with this protocol 2 year
Secondary To Provide Safety and Efficacy Data for to Recommend Further Larger Studies. Number participants with grade 3 and 4 hematologic and non-hematologic toxicities. All toxicities are for end of cycle 2. Two 28 day cycles
See also
  Status Clinical Trial Phase
Completed NCT00003935 - Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma Phase 1
Terminated NCT00107471 - Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma Phase 1/Phase 2
Completed NCT00003573 - Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Phase 2
Recruiting NCT05235074 - OH2 Oncolytic Viral Therapy in Central Nervous System Tumors Phase 1/Phase 2
Suspended NCT05308407 - POWER UP: Participating Online While Exercising to Recover Using Play N/A
Terminated NCT00477503 - Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA Phase 1
Active, not recruiting NCT01985451 - Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Phase 2
Withdrawn NCT00109798 - Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma N/A
Completed NCT00003203 - Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Phase 2
Completed NCT00003141 - Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Phase 1
Completed NCT02462629 - Study of BLZ-100 in Pediatric Subjects With CNS Tumors Phase 1
Active, not recruiting NCT01735747 - Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Phase 2
Recruiting NCT00607984 - Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors N/A
Completed NCT00899834 - DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma N/A
Completed NCT00066248 - Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Phase 2
Completed NCT00187226 - A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Phase 2
Completed NCT02793466 - Durvalumab in Pediatric and Adolescent Patients Phase 1
Withdrawn NCT01052363 - OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Phase 1
Completed NCT00047320 - Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Phase 2
Completed NCT00945828 - Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors N/A